戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ORs that colocalize with the stress hormone, corticotropin releasing factor.
2 e diuretic hormone 44 (DH44), an ortholog of corticotropin-releasing factor.
3 he transmembrane domains of the glucagon and corticotropin releasing factor 1 (CRF1) receptors to dev
4       An orally active clinical candidate of corticotropin-releasing factor 1 (CRF 1) antagonist 1 sh
5 ective, and orally active antagonists of the corticotropin-releasing factor 1 (CRF 1) receptor.
6 ist (eticlopride), D2R agonist (quinpirole), corticotropin-releasing factor 1 (CRF1) antagonist (anta
7 urthermore, pharmacologic inhibition (with a corticotropin-releasing factor 1 receptor antagonist) of
8 derivatives was synthesized and evaluated as corticotropin releasing factor-1 (CRF(1)) receptor antag
9 s was identified as potent and orally active corticotropin-releasing factor-1 (CRF(1)) receptor antag
10 ctive withdrawal-like state characterized by corticotropin-releasing factor-1 (CRF(1)) receptor antag
11                       Evidence suggests that corticotropin-releasing factor-1 (CRF(1)) receptor antag
12 ation of 8, an earlier lead pyrazinone-based corticotropin-releasing factor-1 (CRF(1)) receptor antag
13 rmittent access to palatable food results in corticotropin-releasing factor-1 (CRF1) receptor antagon
14 ed by 8 were potent antagonists of the human corticotropin-releasing factor-1 receptor.
15                                              Corticotropin-releasing factor, a stress-related neurope
16 amine and opioid peptide function, increased corticotropin-releasing factor activity).
17 hine exposure sensitizes the LC-NE system to corticotropin releasing factor and stress.
18 t of brain stress neurotransmitters, such as corticotropin-releasing factor and dynorphin, in the neu
19  alcohol drinking by increased expression of corticotropin-releasing factor and its feedback regulati
20 ween the N/OFQ and Hcrt systems in which the corticotropin-releasing factor and N/OFQ systems coordin
21           This parallels a similar effect of corticotropin-releasing factor and suggests a form of ne
22 by a variety of central (eg, neuropeptide Y, corticotropin-releasing factor, and neuromedin U) and pe
23 oactive intestinal polypeptide, substance P, corticotropin-releasing factor, and neuropeptide Y), ena
24 cial behavior (especially neuropeptide Y and corticotropin-releasing factor) are modulated by alcohol
25                                              Corticotropin releasing factor binding protein (CRF-BP)
26                                              Corticotropin releasing factor-binding protein (CRF-BP)
27 88-induced c-Fos activation were observed in corticotropin releasing factor-containing neurons of the
28 eus of the hypothalamus and primarily in non-corticotropin releasing factor-containing neurons of the
29 gh an interaction between the stress hormone corticotropin releasing factor (CRF) and glutamate relea
30                      The stress neuropeptide corticotropin releasing factor (CRF) and its receptors (
31                    The circadian activity of corticotropin releasing factor (CRF) and the hypothalami
32                                          The corticotropin releasing factor (CRF) antagonist, alpha-h
33 blocked by intravenous pretreatment with the corticotropin releasing factor (CRF) antagonist, astress
34                                              Corticotropin releasing factor (CRF) coordinates the bra
35                                          The corticotropin releasing factor (CRF) family of ligands a
36      Here we demonstrate that, in the vBNST, corticotropin releasing factor (CRF) is expressed in neu
37                                              Corticotropin releasing factor (CRF) is the primary medi
38                                              Corticotropin releasing factor (CRF) is the primary regu
39  of this study was to examine the ability of corticotropin releasing factor (CRF) or antibody to insu
40                                              Corticotropin releasing factor (CRF) plays a major role
41                                      Reduced corticotropin releasing factor (CRF) receptor activity a
42 icotine withdrawal was mediated by increased corticotropin releasing factor (CRF) receptor-1 expressi
43 e agonists and developed antagonists for the corticotropin releasing factor (CRF) receptors are new t
44                                              Corticotropin releasing factor (CRF) regulates physiolog
45 lar nucleus (PVN) have been shown to inhibit corticotropin releasing factor (CRF) synthesis via GABA(
46                                          The corticotropin releasing factor (CRF) system in the centr
47                                          The corticotropin releasing factor (CRF) system in the centr
48                                          The corticotropin releasing factor (CRF) type 1 receptor (CR
49                                              Corticotropin releasing factor (CRF) within the ventral
50 ontains a large number of neurons expressing corticotropin releasing factor (CRF), a neuropeptide tha
51  intracerebroventricular (icv) injections of corticotropin releasing factor (CRF), a putative anxioge
52 hanism underlying this response, we measured corticotropin releasing factor (CRF), an upstream modula
53 analyzed brain regional, CCK-8, substance P, corticotropin releasing factor (CRF), and neuropeptide Y
54  for 15 days and measured mRNA expression of corticotropin releasing factor (CRF), neuropeptide Y (NP
55         Urocortin 1 (Ucn 1) is an endogenous corticotropin releasing factor (CRF)-related peptide.
56 of action for the anxiogenic neuromodulator, corticotropin releasing factor (CRF).
57 ine seeking by the stress-sensitive peptide, corticotropin releasing factor (CRF).
58 presence of the prototypical stress hormone, corticotropin releasing factor (CRF).
59                                The mammalian corticotropin releasing factor (CRF)/urocortin (Ucn) pep
60           Two new classes of tricyclic-based corticotropin-releasing factor (CRF(1)) receptor-1 antag
61 were measured at baseline and in response to corticotropin-releasing factor (CRF) (0.5 microg kg(1))
62 c raphe nucleus, including a coordination of corticotropin-releasing factor (CRF) actions at both of
63                               We report that corticotropin-releasing factor (CRF) acts in the ventral
64 f chronic nicotine SA on the coexpression of corticotropin-releasing factor (CRF) and arginine vasopr
65         Although it has long been known that corticotropin-releasing factor (CRF) and CRF receptors a
66 ocus of the present review is on the role of corticotropin-releasing factor (CRF) and CRF-related pep
67             Long-term alterations in central corticotropin-releasing factor (CRF) and glucocorticoid
68  mRNA was found to partially colocalize with corticotropin-releasing factor (CRF) and growth hormone-
69 ajor site of extrahypothalamic expression of corticotropin-releasing factor (CRF) and its G-protein-c
70                                              Corticotropin-releasing factor (CRF) and its paralogues
71                                              Corticotropin-releasing factor (CRF) and nociceptin/orph
72 laced on the neuropharmacological actions of corticotropin-releasing factor (CRF) and norepinephrine
73                 Release of the neuropeptides corticotropin-releasing factor (CRF) and orexin-A in the
74                                              Corticotropin-releasing factor (CRF) and related peptide
75                                              Corticotropin-releasing factor (CRF) and the closely rel
76              The stress-related neuropeptide corticotropin-releasing factor (CRF) and the serotonin s
77                                              Corticotropin-releasing factor (CRF) and urocortin (Ucn
78         Here we report the identification of corticotropin-releasing factor (CRF) as a critical compo
79                                    Exogenous corticotropin-releasing factor (CRF) but not corticoster
80 ng the endocrine arm of the stress response, corticotropin-releasing factor (CRF) can act in the brai
81 s-induced release of neuromodulators such as corticotropin-releasing factor (CRF) can drive drug-depe
82                               To investigate corticotropin-releasing factor (CRF) contributions to fe
83 ses and how the stress-related neuropeptide, corticotropin-releasing factor (CRF) directs this by a b
84  regulation of the central extrahypothalamic corticotropin-releasing factor (CRF) expression is assoc
85 -term effects of an acute colitis on central corticotropin-releasing factor (CRF) expression.
86                                          The corticotropin-releasing factor (CRF) family of peptides
87                Urocortins are members of the corticotropin-releasing factor (CRF) family of peptides
88         Urocortin 3 (Ucn 3), a member of the corticotropin-releasing factor (CRF) family of peptides,
89                              Peptides of the corticotropin-releasing factor (CRF) family signal throu
90         Urocortin 2 (Ucn 2), a member of the corticotropin-releasing factor (CRF) family, and its cog
91         Urocortin 2 (Ucn2), a peptide of the corticotropin-releasing factor (CRF) family, binds with
92  hypersecretion of the stress neuromediator, corticotropin-releasing factor (CRF) has been implicated
93 rofiling of relevant PI cells identified the corticotropin-releasing factor (CRF) homolog, DH44, as a
94 ike ShA cocaine self-administration, reduced corticotropin-releasing factor (CRF) immunodensity in th
95                       The role of amygdaloid corticotropin-releasing factor (CRF) in alcoholism is no
96 gates the regulation of cytosolic calcium by corticotropin-releasing factor (CRF) in midbrain dopamin
97 ed body of work indicates a crucial role for corticotropin-releasing factor (CRF) in neurobiological
98 vioral studies support a modulatory role for corticotropin-releasing factor (CRF) in regulating the d
99 termined the role of the stress neurohormone corticotropin-releasing factor (CRF) in stress-induced b
100  was used to study immunoreactivity (IR) for corticotropin-releasing factor (CRF) in the guinea pig e
101 ed on previous work hypothesizing a role for corticotropin-releasing factor (CRF) in the IC during cr
102 lores the relationship between dynorphin and corticotropin-releasing factor (CRF) in the induction of
103 halin (ENK)] with the stress-related peptide corticotropin-releasing factor (CRF) in the LC.
104 bout the distribution of the stress hormone, corticotropin-releasing factor (CRF) in the mouse brain.
105       We recently described the existence of corticotropin-releasing factor (CRF) in the mouse cochle
106 dies have found that the stress neurohormone corticotropin-releasing factor (CRF) inhibits 5-HT neuro
107  literature suggests that catecholamines and corticotropin-releasing factor (CRF) interact in a seria
108    Stress induces the release of the peptide corticotropin-releasing factor (CRF) into the ventral te
109                                              Corticotropin-releasing factor (CRF) is a key mediator o
110                                              Corticotropin-releasing factor (CRF) is also known as a
111                                              Corticotropin-releasing factor (CRF) is an important lin
112                             The neuropeptide corticotropin-releasing factor (CRF) is believed to play
113                                              Corticotropin-releasing factor (CRF) is critical for the
114                                              Corticotropin-releasing factor (CRF) is expressed in the
115 ntial findings suggest that the neuropeptide corticotropin-releasing factor (CRF) is instrumental in
116                                              Corticotropin-releasing factor (CRF) is the major physio
117                                          The corticotropin-releasing factor (CRF) ligand family has d
118                                              Corticotropin-releasing factor (CRF) mediates anxiogenic
119     The present experiments examined whether corticotropin-releasing factor (CRF) modulates memory co
120 rning of day 15, we measured AT(1) receptors corticotropin-releasing factor (CRF) mRNA and immunoreac
121                                              Corticotropin-releasing factor (CRF) mRNA expression in
122 rsal mPFC enhanced restraint-induced Fos and corticotropin-releasing factor (CRF) mRNA expression in
123 re to elicit reliable increases in Fos-ir or corticotropin-releasing factor (CRF) mRNA in the PVH.
124 ysis of Fos induction and relative levels of corticotropin-releasing factor (CRF) mRNA.
125 and anxiety and activates a subpopulation of corticotropin-releasing factor (CRF) neurons in the bed
126 cohol intake specifically recruited GABA and corticotropin-releasing factor (CRF) neurons in the mPFC
127                           Antagonists of the corticotropin-releasing factor (CRF) neuropeptide should
128  the relationship between corticosterone and corticotropin-releasing factor (CRF) on both beta-amyloi
129 ed the effect of an intravenous injection of corticotropin-releasing factor (CRF) on fructose malabso
130 nced fear memory but did not increase either corticotropin-releasing factor (CRF) or corticosterone.
131                                 Injection of corticotropin-releasing factor (CRF) or urocortin III, k
132                                              Corticotropin-releasing factor (CRF) orchestrates the st
133                                          The corticotropin-releasing factor (CRF) peptide family is a
134                                          The corticotropin-releasing factor (CRF) peptide hormone fam
135                                      Because corticotropin-releasing factor (CRF) plays a role in str
136          Considerable evidence suggests that corticotropin-releasing factor (CRF) plays an important
137                                          The corticotropin-releasing factor (CRF) receptor 1 (CRFR1)
138 duction and Abeta elevation are dependent on corticotropin-releasing factor (CRF) receptor 1 signalin
139                                              Corticotropin-releasing factor (CRF) receptor activation
140                                          The corticotropin-releasing factor (CRF) receptor CRFR2 is e
141                                              Corticotropin-releasing factor (CRF) receptor subtypes 1
142                                          The corticotropin-releasing factor (CRF) receptors (CRF1 and
143                                              Corticotropin-releasing factor (CRF) receptors are found
144                                      Because corticotropin-releasing factor (CRF) receptors are impli
145                                              Corticotropin-releasing factor (CRF) receptors have been
146 ife social isolation increases the levels of corticotropin-releasing factor (CRF) receptors in the se
147                                              Corticotropin-releasing factor (CRF) receptors-which bin
148             The stress-related neuropeptide, corticotropin-releasing factor (CRF) regulates the dorsa
149 induced relapse through alterations in brain corticotropin-releasing factor (CRF) regulation of neuro
150                                              Corticotropin-releasing factor (CRF) signaling at the CR
151                               Alterations in corticotropin-releasing factor (CRF) signaling pathways
152                                Activation of corticotropin-releasing factor (CRF) signaling pathways
153                   Over the past few decades, corticotropin-releasing factor (CRF) signaling pathways
154 o negative reinforcement is a recruitment of corticotropin-releasing factor (CRF) signaling within th
155   Previous studies have implicated the brain corticotropin-releasing factor (CRF) stress systems in m
156 likely resulting from dysregulation of brain corticotropin-releasing factor (CRF) stress systems.
157 ment of the extrahypothalamic stress peptide corticotropin-releasing factor (CRF) system and activati
158                         Dysregulation of the corticotropin-releasing factor (CRF) system has been imp
159                                          The corticotropin-releasing factor (CRF) system is the prima
160 ess systems, including the extrahypothalamic corticotropin-releasing factor (CRF) system, following l
161                                          The corticotropin-releasing factor (CRF) system, which is in
162 f neonatal amygdala (Neo-A) lesions on brain corticotropin-releasing factor (CRF) systems and hypotha
163                                          The corticotropin-releasing factor (CRF) type 1 receptor (CR
164                         Systemic blockade of corticotropin-releasing factor (CRF) type 1 receptors (C
165  authors investigated the effect of blocking corticotropin-releasing factor (CRF) Type I and Type II
166             The authors investigated whether corticotropin-releasing factor (CRF) within the central
167                                              Corticotropin-releasing factor (CRF), a 41 amino acid pe
168                          Here we report that corticotropin-releasing factor (CRF), a neuropeptide rel
169          The bimolecular interaction between corticotropin-releasing factor (CRF), a neuropeptide, an
170 -regulated by a major stress neuromodulator, corticotropin-releasing factor (CRF), acting on CRF type
171         The authors tested whether decreased corticotropin-releasing factor (CRF), an activator of fe
172 nsistent with this, the CEA highly expresses corticotropin-releasing factor (CRF), an important modul
173 ceruleus (LC)-norepinephrine (NE) neurons to corticotropin-releasing factor (CRF), an integral mediat
174 ays a role in the relationship among stress, corticotropin-releasing factor (CRF), and alcohol abuse.
175 he LC include excitatory amino acids (EAAs), corticotropin-releasing factor (CRF), and endogenous opi
176 (Dh44), a neuropeptide related to vertebrate corticotropin-releasing factor (CRF), and its receptor,
177 vitro and their modulation by dopamine (DA), corticotropin-releasing factor (CRF), and their combinat
178                   The neuroactive substances corticotropin-releasing factor (CRF), arginine-vasopress
179 to the BNSTDL, is thought to communicate via corticotropin-releasing factor (CRF), but studies have y
180                            The neuropeptide, corticotropin-releasing factor (CRF), coordinates the ph
181                                              Corticotropin-releasing factor (CRF), encoded by the CRH
182 -protein-coupled receptor B1 family includes corticotropin-releasing factor (CRF), growth hormone-rel
183 -adrenal (HPA) axis-activating neuropeptide, corticotropin-releasing factor (CRF), may be the keyston
184 ological studies indicate the involvement of corticotropin-releasing factor (CRF), noradrenaline, dop
185                                              Corticotropin-releasing factor (CRF), originally charact
186                                              Corticotropin-releasing factor (CRF), the major stress p
187             The focus is on the receptor for corticotropin-releasing factor (CRF), the orchestrator o
188                                              Corticotropin-releasing factor (CRF), the stress-related
189     Stress may impact on this system through corticotropin-releasing factor (CRF), which densely inne
190 ral amygdala noradrenergic substrates [via a corticotropin-releasing factor (CRF)-dependent mechanism
191 lacement regimens were tested for changes in corticotropin-releasing factor (CRF)-enhanced startle (i
192 allenge has been shown previously to cause a corticotropin-releasing factor (CRF)-mediated increase i
193                                              Corticotropin-releasing factor (CRF)-mediated mechanisms
194                                              Corticotropin-releasing factor (CRF)-related peptides ca
195                                              Corticotropin-releasing factor (CRF)-related peptides mo
196                                              Corticotropin-releasing factor (CRF)-related peptides se
197 agonists for the stress-related neurohormone corticotropin-releasing factor (CRF).
198 amygdala (CeA) that produce the neuropeptide corticotropin-releasing factor (CRF).
199    A major determinate of these responses is corticotropin-releasing factor (CRF).
200 n the lateral parabrachial nucleus coexpress corticotropin-releasing factor (CRF).
201 ntracerebroventricular infusion of saline or corticotropin-releasing factor (CRF).
202 action of the stress-associated neurohormone corticotropin-releasing factor (CRF).
203 nent of the stress response activated by the corticotropin-releasing factor (CRF).
204 d reward, including neuropeptide Y (NPY) and corticotropin-releasing factor (CRF).
205 vation of glucocorticoid receptors (GRs) and corticotropin-releasing factor (CRF).
206 ation of VTA dopaminergic neurons expressing corticotropin-releasing factor (CRF).
207 ) system by the stress-related neuropeptide, corticotropin-releasing factor (CRF).
208  two endogenous CRF-related peptide ligands, corticotropin-releasing factor [CRF rat/human (r/h)] and
209 known as maternal aggression) is impaired by corticotropin-releasing factor-(CRF) related peptides, b
210 ed neural cell density, stress neuropeptide (corticotropin releasing factor--CRF) levels, and plasma
211    This study tested the hypothesis that the corticotropin-releasing factor (CRF1) antagonist GSK5616
212 ers of the corticoliberin family include the corticotropin releasing factors (CRFs), sauvagine, the u
213 rmones and is transcriptionally activated in corticotropin releasing factor-expressing cells.
214 ed with brain region-specific alterations of corticotropin-releasing factor expression and promoter m
215            The neuropeptides vasopressin and corticotropin-releasing factor facilitate, while seroton
216 oupled receptors, which bind peptides of the corticotropin releasing factor family and are key mediat
217  fashion both NGF and the hormone urotensin (corticotropin-releasing factor family ligand).
218 ortin 2, a recently identified member of the corticotropin-releasing factor family, is expressed in d
219 ivery of Urocortin I (UcnI), a member of the corticotropin-releasing factor family, suppresses feedin
220 ylglycines (NPPGs) as a novel class of human corticotropin releasing factor (h-CRF(1)) antagonists.
221       They further suggest that an activated corticotropin-releasing factor/hypothalamic-pituitary-ad
222 ephalin, thyrothropin-releasing hormone, and corticotropin-releasing factor immunoreactive cells in t
223 CRFR1) mediates the physiological actions of corticotropin-releasing factor in the anterior pituitary
224 doxical observations of increased release of corticotropin-releasing factor in the face of low cortis
225 tuitary-adrenal axis, including signaling by corticotropin-releasing factor, in the pathophysiology o
226                                              Corticotropin-releasing factor infusions into LA impair
227                                              Corticotropin-releasing factor infusions into the centra
228              Neuroendocrine hormones such as corticotropin-releasing factor, leptin and alpha-melanoc
229 in abnormal cerebrospinal fluid cortisol and corticotropin-releasing factor levels.
230 ated increments in restraint-induced Fos and corticotropin-releasing factor mRNA expression in the ne
231 w stress interacts with the neuromodulators, corticotropin-releasing factor, norepinephrine, dopamine
232 w explores the role of brain stress systems (corticotropin-releasing factor, norepinephrine, orexin [
233 s in the anterior hypothalamus that may gate corticotropin-releasing factor output from the amygdala
234 s an activation of the brain stress system's corticotropin-releasing factor outside of the hypothalam
235 in stress and appetite regulation, including corticotropin releasing factor, pro-opiomelanocortin B,
236                  In our continued studies on corticotropin releasing factor receptor (CRFR1) signalin
237    The CRF system consists of two receptors, corticotropin releasing factor receptor 1 (CRF1R) and co
238 technique to a member of a class B GPCR, the corticotropin releasing factor receptor 1 (CRF1R).
239 opin releasing factor receptor 1 (CRF1R) and corticotropin releasing factor receptor 2 (CRF2R), a non
240  analysis showed significant upregulation of corticotropin releasing factor receptor 2 (CrfR2) in the
241       The current study examines the role of corticotropin releasing factor receptor subtypes 1 and 2
242 nvestigated here the interaction between the corticotropin releasing factor receptor type 1 (CRF1R) a
243 tuted pyridyl)pyrazolo[1,5-a]-1,3,5-triazine corticotropin releasing factor receptor-1 (CRF(1)) recep
244 methoxyphenyl)pyrazolo[1,5-a]-1,3,5-triazine corticotropin releasing factor receptor-1 (CRF(1)) recep
245 cyclic imidazo[4,5-b]pyridin-2-ones as human corticotropin-releasing factor receptor (CRF(1)) antagon
246 ss, the physiological consequence of central corticotropin-releasing factor receptor (CRF-R) activati
247 viously reported differential involvement of corticotropin-releasing factor receptor (CRFR) 1 and 2 i
248 c disruption of signaling through the type 1 corticotropin-releasing factor receptor (CRFR1).
249              Administration of the selective corticotropin-releasing factor receptor 1 (CRF(1)) antag
250     In addition, we examined the role of the corticotropin-releasing factor receptor 1 (CRF(1)) in th
251  We aimed to characterize the effects of the corticotropin-releasing factor receptor 1 (CRF-R1) antag
252  noradrenergic (NE) receptors (alpha1) via a corticotropin-releasing factor receptor 1 (CRF-R1)-depen
253 rial evaluating the efficacy of GSK561679, a corticotropin-releasing factor receptor 1 (CRF1 receptor
254                          We describe a novel corticotropin-releasing factor receptor 1 (CRF1) antagon
255                                  Blockade of corticotropin-releasing factor receptor 1 (CRF1) suppres
256                                              Corticotropin-releasing factor receptor 1 (CRFR1) mediat
257  Similarly to what has been observed for the corticotropin-releasing factor receptor 1 (CRFR1), SAP97
258 me proliferator-activated receptor gamma and corticotropin-releasing factor receptor 1 were notable e
259 ecifically activated by either neurokinin I, corticotropin-releasing factor receptor 1, or dopamine D
260                            Mice deficient in corticotropin-releasing factor receptor 2 (CRF2) (C57BL/
261  mutants with constitutive activation of the corticotropin-releasing factor receptor family homologue
262 d, we took the CRF(2(a))R and the homologous corticotropin-releasing factor receptor type 1 (CRF(1)R)
263 esent study investigated whether blockade of corticotropin-releasing factor receptor type 1 (CRF-R1)
264 n reflect reductions in anandamide driven by corticotropin-releasing factor receptor type 1 (CRF1) po
265  we investigated interactions of the class B corticotropin-releasing factor receptor type 1 (CRF1R) w
266                                              Corticotropin-releasing factor receptor type 1 (CRFR1) i
267 ular membrane compartments, we show that the corticotropin-releasing factor receptor type 1 has a spe
268 ure of the transmembrane domain of the human corticotropin-releasing factor receptor type 1 in comple
269                                          The corticotropin-releasing factor receptor type 1 is a clas
270 here this equilibrium is established for the corticotropin-releasing factor receptor type 1.
271                                              Corticotropin-releasing factor receptor type 2 (CRFR2) h
272 vation of the central stress response, while corticotropin-releasing factor receptor type 2 (CRFR2) h
273 eviously, we observed abnormal expression of corticotropin-releasing factor receptor type 2 (CRFR2) t
274                                          The corticotropin-releasing factor receptor type 2a (CRF(2(a
275 ing affinity of 4-anilinopyrimidines against corticotropin-releasing factor receptor-1 (CRF(1)) (e.g.
276                                              Corticotropin-releasing factor receptor-1 (CRF(1)) media
277 n in the BNST is unaffected by alpha1-AR and corticotropin-releasing factor receptor-1 (CRFR(1)) anta
278  Effects on attention were attenuated by the corticotropin-releasing factor receptor-1 antagonist ant
279 NMR structure of the analogous domain of the corticotropin-releasing factor receptor.
280                                              Corticotropin-Releasing Factor Receptors (CRFRs) are cla
281                                              Corticotropin-releasing factor receptors (CRFRs), class
282                       Alterations in central corticotropin-releasing factor signaling pathways have b
283 ry-adrenal axis), (4) the (gastrointestinal) corticotropin-releasing factor system, and (5) the intes
284                                 In addition, corticotropin-releasing factor systems were shown to fac
285 is function was probed using a dexamethasone/corticotropin-releasing factor test.
286 ess effect by counteracting the functions of corticotropin-releasing factor, the primary stress-media
287 peptides (ghrelin, nesfatin-1, somatostatin, corticotropin-releasing factor, thyrotropin-releasing ho
288                                              Corticotropin releasing factor type 1 (CRF1) is a key co
289     This hypothesis was investigated for the corticotropin-releasing factor type 1 (CRF(1)) receptor
290 A, alpha(1b) adrenergic (alpha(1b) ADR), and corticotropin-releasing factor type 1 (CRF-R1) and 2 (CR
291 hich oxytocin (OTR), vasopressin (V1aR), and corticotropin-releasing factor type 1 (CRF1) or type 2 r
292                                Activation of corticotropin-releasing factor type 1 (CRF1) receptors i
293 icated that repeated social stress decreased corticotropin-releasing factor type 1 receptor and incre
294                                We found that corticotropin-releasing factor type 1 receptor within th
295 disrupts this LTCC-based mechanism; instead, corticotropin-releasing factor type 1 receptors (CRF1s)
296 disrupts this LTCC-based mechanism; instead, corticotropin-releasing factor type 1 receptors (CRF1s)
297 re sensitive to central anorectic effects of corticotropin-releasing factor type 2 (CRF(2)) receptor
298                                          The corticotropin-releasing factor type 2 receptor (CRFR2) i
299 demonstrated that the mechanism involved the corticotropin-releasing factor type 2 receptor, cAMP ele
300 n the amygdala, which required activation of corticotropin-releasing factor type-1 (CRF-R1) receptors

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。
 
Page Top